Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.
The company will highlight expanded product offerings and other 3D applications in oncology, neuroscience, toxicity screening, and more. Corning experts will be able to speak to these applications, the impact of 3D in research and development and drug discovery, as well as perspectives in disease modeling and high-throughput screening.
Discussion topics will include how the use of physiologically relevant 3D cell cultures is facilitating discovery and validation of novel drug targets and accelerating clinical translation of drug candidate screening for safety and efficacy. Spokespeople will be available for tours and to share insights at booth #413.
Corning and its customers will also offer several presentations and posters during SLAS including:
Presentations and Tutorials
- Sunday, February 3, 2019
Short Course: Set-up and Validation of 3D Primary, Stem Cell and Immortalized Cultures for Downstream Microplate Reader and Imaging Applications
Presented by: Brad Larson, BioTek Instruments, Inc., Mark E. Rothenberg Ph.D., Corning Life Sciences
8:00 a.m. – 12:00 p.m.
Convention Center, room 143C
- Monday, February 4, 2019
Tutorial: Spheroids and Mini Brains for Studying Glioblastoma
Presented by: Amanda Linkous, Ph.D., NCI Center for Systems Biology of Small Cell Lung Cancer at Vanderbilt, Hilary Sherman, Corning Life Sciences
2:00 – 2:45 p.m.
Convention Center, Room 151A
- Tuesday, February 5, 2019
Podium Presentation: Fully Automated Large Scale uHTS using 3D Cancer Organoid Models for Phenotypic Drug Discovery Applications
Presented by: Virneliz Fernandez Vega, Scripps Research Institute
12:00 – 12:30 p.m.
- Wednesday, February 6, 2019
Podium Presentation: High-throughput, CRISPR Based 3D Screening Platform for Rapid Discovery of Novel CDK4/6 Inhibitor Resistance
Presented by: Taraka Sai Pavan Grandhi, Ph.D, Genomics Institute of Novartis Research Foundation
11:00 AM - 11:30 AM
Corning Life Sciences and its customers will be presenting several posters throughout the meeting including those focused on high-throughput screening, 3D assay development, air-liquid interface models and other 3D application areas.
If you are interested in scheduling a booth tour and meeting with a member of the Corning team to learn more about how Corning is transforming and enabling the future of 3D with innovative technologies and workflow solutions, please contact:
About Corning Incorporated
Corning (www.corning.com) is one of the world's leading innovators in materials science, with a more than 165-year track record of life-changing inventions. Corning applies its unparalleled expertise in glass science, ceramic science, and optical physics along with its deep manufacturing and engineering capabilities to develop category-defining products that transform industries and enhance people's lives. Corning succeeds through sustained investment in RD&E, a unique combination of material and process innovation, and deep, trust-based relationships with customers who are global leaders in their industries.
Corning's capabilities are versatile and synergistic, which allows the company to evolve to meet changing market needs, while also helping our customers capture new opportunities in dynamic industries. Today, Corning's markets include optical communications, mobile consumer electronics, display technology, automotive, and life sciences vessels. Corning's industry-leading products include damage-resistant cover glass for mobile devices; precision glass for advanced displays; optical fiber, wireless technologies, and connectivity solutions for state-of-the-art communications networks; trusted products to accelerate drug discovery and delivery; and clean-air technologies for cars and trucks.